Применение и эффективность «Спленопида» и «Ронколейкина» в лечении гнойно-воспалительных и иммунодефицитных заболеваний

Aim. The aim of the study was to estimate the efficiency of the drugs splenopid and roncoleukin for the treatment of a severe purulo-necrotic pathology in patients of Izhevsk Regional Clinical Hospital № 1. Materials and methods. The results of treatment of 125 patients with severe purulo-septic pathology of the abdominal cavity and retroperitoneal space are presented in the paper. All patients were divided into 2 groups: group 1 (50 persons) took “Splenopid”, group 2 (60 persons) “Roncoleukin”. The control group included 15 persons, who experienced traditional methods of treatment. The patients’ status was assessed by toxicological, immunological and biochemical indices. Results. Among the patients taking splenopid, positive dynamics in immunological status was detected at the days 4-7. In the control group, all cellular immunity indices were below the norm. The patients receiving roncoleukin had positive immunological dynamics at the days 3-5, which was accompanied by the activation of initially decreased cellular component of the immune system. Conclusions. A high activity of these drugs was stated in different degrees of immunological deficiency, in treatment of pyoinflammatory diseases of the abdominal cavity, small pelvis organs, septic states. The cellular and humoral immunity indices in the group of patients receiving ronkoleukin are higher that can prove its greater efficiency.